Former CBER director warns FDA staff cuts could upend drug review timelines as early as next year: BMO
In an interview with BMO Capital Markets, a prominent former FDA official has sounded the alarm about the potential for mass layoffs at the agency to disrupt the agency's drug review process. The threat, which would be particularly pronounced for rare disease and cell and gene therapy programs, could set in as early as 2026.
In an interview with BMO Capital Markets, a prominent former FDA official has sounded the alarm about the potential for mass layoffs at the agency to disrupt the agency's drug review process. The threat, which would be particularly pronounced for rare disease and cell and gene therapy programs, could set in as early as 2026.
